Pivotal Year Ahead For Spain's PharmaMar
After Record Revenues In 2020
The Madrid-based group's Aplidin is set to go back yet again to European regulators but the sea squirt-derived drug seems to be showing more potential in COVID-19 than in multiple myeloma.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
Spain has suffered more than most from COVID-19 but the life sciences sector is exploring a variety of ways to tackle the coronavirus pandemic.